Parental Fab liabilities can dictate the fate of final bispecific assembly, often guided by the "Rule of Additivity." This webinar explores how parental mAb profiling and a systematic bispecific ...
Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results